<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14828">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01729208</url>
  </required_header>
  <id_info>
    <org_study_id>CVI08008</org_study_id>
    <nct_id>NCT01729208</nct_id>
  </id_info>
  <brief_title>An Evaluation of the Effectiveness of Dual Focus Soft Contact Lenses in Slowing Mypoia Progression</brief_title>
  <official_title>A Multicentre Dispensing Clinical Evaluation of MiSightÂ® Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coopervision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Visioncare Research Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Coopervision, Inc.</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a new type of soft contact lens with a
      unique optical design (dual focus) is effective at slowing the progression of myopia
      (near-sightedness) in children.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in refractive error relative to baseline</measure>
    <time_frame>yearly for 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in axial length relative to baseline</measure>
    <time_frame>yearly for 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Dual Focus Soft Contact Lens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dual Focus Soft Contact Lens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Vision Soft Contact Lens</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single Vision Soft Contact Lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dual Focus Soft Contact Lens</intervention_name>
    <arm_group_label>Dual Focus Soft Contact Lens</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Single Vision Soft Contact Lens</intervention_name>
    <arm_group_label>Single Vision Soft Contact Lens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be between 8 and 12 years of age inclusive.

          -  Best-corrected visual acuity by manifest refraction of +0.10 logMAR.

          -  Spherical Equivalent Refractive Error between -0.75 and -4.00 D inclusive
             astigmatism: &lt; -0.75 D anisometropia: &lt; 1.00 D

          -  Possess wearable and visually functional eyeglasses.

          -  Agree to wear the assigned contact lenses for a minimum of 10 hours per day, - at
             least 6 days per week, for the duration of the 3 year study.

        Exclusion Criteria:

          -  Subject has previously or currently wears contact lenses or rigid gas permeable
             contact lenses, including orthokeratology lenses.

          -  Subject is currently or within 30 days prior to this study has been an active
             participant in another clinical study.

          -  Current or prior use of bifocals, progressive addition lenses, atropine, pirenzepine
             or ANY other myopia control treatment.

          -  Regular use of ocular medications (prescription or over-the-counter), artificial
             tears, or wetting agents.

          -  Current use of systemic medications which may significantly affect contact lens wear,
             tear film production, pupil size, accommodation or refractive state.

          -  A known allergy to fluorescein, benoxinate, proparacaine or tropicamide.

          -  Strabismus by cover test at far (4 m) or near (40 cm) wearing distance correction.

          -  Any ocular, systemic or neuro-developmental conditions that could influence
             refractive development.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Waterloo School of Optometry</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2L 3G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minho Clinical &amp; Experiment Optometry Research Lab</name>
      <address>
        <city>Braga</city>
        <zip>4710-057</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University of Singapore Faculty of Medicine</name>
      <address>
        <city>Singapore</city>
        <zip>117597</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aston University Ophthalmic Research Group</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 7ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Portugal</country>
    <country>Singapore</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 3, 2014</lastchanged_date>
  <firstreceived_date>November 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myopia progression</keyword>
  <keyword>myopia control</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
